Taiwan FDA registration 52e5e87c50ee975d53893be204eecdca
Bondis Oppro C1 Deactivator Analysis Kit
TW: 邦迪斯歐普羅C1去活化劑分析套組
Taiwan·Risk Class 2·THE BINDING SITE GROUP LTD·Registered May 18, 2021 – May 18, 2026ExpiredRegistration details
- Analysis ID
- 52e5e87c50ee975d53893be204eecdca
- Customs Code
- DHA05603465603
Company information
- Manufacturer
- THE BINDING SITE GROUP LTD
- Manufacturer Country
- United Kingdom
- Authorized Representative
- EVERLIGHT BIOTECH(TAIWAN) CO., LTD.
Product details
- Intended Use
- This product is used with the Bondis Optilite analyzer for in vitro quantification of C1 deactivators present in serum.
- Product Type (Level 1)
- C Immunology and microbiology
- Product Type (Level 2)
- C.5250 補體C1抑制劑(去活化劑)免疫試驗系統
- Import Information
- Input;; QMS/QSD
Dates and status
- Registration Date
- May 18, 2021
- Expiry Date
- May 18, 2026
About this record
Access comprehensive regulatory information for Bondis Oppro C1 Deactivator Analysis Kit in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 52e5e87c50ee975d53893be204eecdca and manufactured by THE BINDING SITE GROUP LTD. The authorized representative in Taiwan is EVERLIGHT BIOTECH(TAIWAN) CO., LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices